Dyadic International (DYAI) Net Margin (2018 - 2026)
Dyadic International's (DYAI) quarterly Net Margin came in at 171.91% in Q1 2026, up 33708.0% year-over-year from N/an in Q1 2025, and up 36.05% quarter-over-quarter from 268.83% in Q4 2025.
Analysis
Dyadic International (DYAI) Net Margin (2018 - 2026) Analysis & Trends
Dyadic International has disclosed Net Margin across 9 years of filings, most recently posting 171.91% for Q1 2026.
- In Q1 2026, Net Margin rose 33708.0% year-over-year to 171.91%; the TTM figure through Mar 2026 stood at 187.71% (down 2803.0% YoY), while the FY2025 annual figure was 234.3%, down 7032.0% from the prior year.
- Net Margin came in at 171.91% for Q1 2026 at Dyadic International, up from 268.83% in the prior quarter.
- In the past five years, Net Margin ranged from a high of 8.38% in Q3 2024 to a low of 615.56% in Q1 2024.
- Average Net Margin over 5 years is 306.47%, with a median of 268.83% recorded in 2025.
- Year-over-year, Net Margin surged 105643 bps in 2022 and plunged 41661 bps in 2024.
- Over 5 years, Net Margin stood at 288.6% in 2022, then fell by 5 bps to 301.78% in 2023, then surged by 39 bps to 185.39% in 2024, then sank by 45 bps to 268.83% in 2025, then surged by 36 bps to 171.91% in 2026.
- Per Business Quant data, the three most recent Net Margin figures were 171.91% in Q1 2026, 268.83% in Q4 2025, and 167.25% in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 206.44 Bn | 192.45 Bn | 7.24 Bn | 23.62% |
| 2 | Gilead Sciences | 179.97 Bn | 176.79 Bn | 6.22 Bn | -134.51% |
| 3 | Vertex Pharmaceuticals | 130.57 Bn | 122.72 Bn | 2.84 Bn | 32.99% |
| 4 | Regeneron Pharmaceuticals | 81.63 Bn | 73.63 Bn | 3.93 Bn | 30.23% |
| 5 | Argenx Se | 60.34 Bn | 55.16 Bn | 1.37 Bn | 31.16% |
| 6 | Moderna | 54.37 Bn | 49.23 Bn | 52.00 Mn | -539.31% |
| 7 | Alnylam Pharmaceuticals | 33.07 Bn | 29.76 Bn | 992.69 Mn | 12.74% |
| 8 | Biogen | 31.84 Bn | 30.55 Bn | 1.96 Bn | 3.56% |
| 9 | Roivant Sciences | 29.49 Bn | 29.49 Bn | 1.16 Mn | -20,152.98% |
| 10 | Dyadic International | 17.78 Mn | 9.82 Mn | - | -171.91% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Mar 31, 2026 | -171.91% |
| Dec 31, 2025 | -268.83% |
| Sep 30, 2025 | -167.25% |
| Jun 30, 2025 | -183.05% |
| Mar 31, 2025 | -508.99% |
| Dec 31, 2024 | -185.39% |
| Sep 30, 2024 | -8.38% |
| Jun 30, 2024 | -516.40% |
| Mar 31, 2024 | -615.56% |
| Dec 31, 2023 | -301.78% |
| Sep 30, 2023 | -406.55% |
| Jun 30, 2023 | -260.55% |
| Mar 31, 2023 | -198.94% |
| Dec 31, 2022 | -288.60% |
| Sep 30, 2022 | -205.68% |
| Jun 30, 2022 | -499.28% |
| Mar 31, 2022 | -422.82% |
| Dec 31, 2021 | -1,345.03% |
| Sep 30, 2021 | -479.24% |
| Jun 30, 2021 | -410.44% |